TLR4/MYD88 pathway dysregulation drives breast cancer progression in Egyptian women

In a study that could reshape how clinicians think about the inflammatory underpinnings of breast cancer, researchers in Egypt have found that two genes at the heart of the innate immune system—TLR4 and MYD88—are markedly overactive in women with breast cancer, and that measuring their expression in blood can distinguish patients from healthy individuals with striking accuracy. The work, published in Molecular Biology Reports, followed 71 Egyptian women with breast cancer and 70 age-matched healthy controls, and its results point to a signaling pathway long known for fighting infection as a potential new biomarker and therapeutic target in tumor progression.

The pathway in question begins with Toll-like receptor 4, or TLR4, a pattern-recognition receptor anchored in the membranes of immune cells and, as it turns out, many cancer cells. TLR4 evolved to detect lipopolysaccharide, a molecular signature of Gram-negative bacteria, and upon binding its ligand it recruits an adaptor protein called myeloid differentiation primary response 88, or MYD88, to the cytoplasmic tail of the receptor. This recruitment sets off a signaling cascade that activates the transcription factor nuclear factor-kappa B (NF-κB), driving the production of inflammatory cytokines such as tumor necrosis factor-alpha and interleukin-6. In the context of infection, this is a rapid and essential defense. But in cancer, chronic activation of the same circuitry can become a double-edged sword: persistent NF-κB signaling promotes proliferation, survival, invasion, and resistance to cell death within the tumor microenvironment.

Previous laboratory studies had already implicated the TLR4/MYD88 axis in the metastatic behavior of breast cancer cells. Experiments have shown that TLR4/MyD88 signaling helps determine the metastatic potential of breast cancer cells, that lipopolysaccharide stimulation can drive metastasis through the Akt/GSK3β/β-catenin pathway, and that blocking TLR4-mediated NF-κB signaling suppresses tumorigenesis in preclinical models. Other work linked elevated MYD88 to resistance against paclitaxel, one of the most widely used chemotherapy agents in breast cancer treatment. What had been missing was robust clinical evidence from patient cohorts measuring gene expression directly, particularly from the Middle East and North Africa region, where breast cancer tends to present at younger ages and more advanced stages than in Western countries.

The Mansoura University research team, led by Sulaiman Mohammed Alshaban of the Faculty of Science’s Biochemistry Division together with colleagues from the university’s Oncology Center, set out to close that gap. They enrolled 71 females diagnosed with breast cancer and 70 healthy females matched by age, collecting peripheral blood samples from all participants. From these samples, the team performed laboratory investigations including measurement of the established tumor markers carbohydrate antigen 15-3 (CA 15-3) and carcinoembryonic antigen (CEA), and quantified TLR4 and MYD88 gene expression using reverse transcription polymerase chain reaction (RT-PCR), a technique that converts messenger RNA into complementary DNA and amplifies it to measure how actively the genes are being transcribed.

The results were unambiguous. The breast cancer group showed a significant increase in both tumor markers compared with the controls, consistent with the established role of CA 15-3 and CEA in monitoring breast cancer. More importantly, expression of TLR4 and MYD88 was significantly elevated in the patients relative to healthy individuals. When the researchers stratified patients by surrogate molecular subtypes—the clinically used classifications based on hormone receptor and HER2 status that guide treatment decisions—they observed a gradual increase in the expression levels of both genes across the subtypes, with significant differences relative to the control group. This gradient suggests that the inflammatory signaling pathway does not merely switch on in cancer but scales with the biology of the disease.

The diagnostic power of the two genes was assessed using receiver operating characteristic (ROC) curve analysis, a statistical method that plots true-positive rate against false-positive rate across different thresholds. TLR4 achieved an area under the curve (AUC) of 0.966, while MYD88 reached 0.900. An AUC of 1.0 represents perfect discrimination and 0.5 represents a coin flip, so values this high indicate that blood-based expression of these genes could separate breast cancer patients from healthy controls with strong discriminating ability—comparable to, or exceeding, the performance of many conventional markers. The authors concluded that TLR4 and MYD88 were elevated significantly in the breast cancer group with strong discriminating power, estimating their association with breast cancer progression.

The findings carry weight beyond diagnostics. If TLR4/MYD88 signaling genuinely drives tumor progression, pharmacological inhibition of the pathway becomes an attractive strategy, and several avenues are already under exploration. Small-molecule TLR4 antagonists are being investigated against triple-negative breast cancer progression, compounds that target MYD88 homodimerization have shown promise in preventing colitis-associated colorectal cancer in animal models, and computational screens have identified candidate inhibitors of MYD88-dependent signaling. Natural products such as atractylenolide-I, which suppresses TLR4-mediated NF-κB signaling, and ursolic acid, which reverses paclitaxel chemoresistance by targeting the miRNA-149-5p/MYD88 axis, offer additional starting points for drug development. A simple blood test showing that these genes are activated in patients strengthens the case that such therapies would reach their intended targets in the clinic.

The study also fits into a broader re-evaluation of innate immunity’s role in cancer. Toll-like receptors are being explored both as targets to block—when their signaling fuels tumor growth and chemoresistance—and as tools to stimulate, since TLR4 activation can sometimes enhance anti-tumor immune responses, as demonstrated in osteosarcoma models where TLR4 signaling inhibited progression by stimulating CD8-positive cytotoxic lymphocytes. This context-dependent behavior underscores why clinical measurement matters: knowing whether a patient’s tumor milieu is dominated by pro-tumorigenic inflammatory signaling, as the elevated MYD88 expression observed here suggests, could inform whether pathway inhibition is likely to help. MYD88 is particularly appealing as a target because it sits downstream of multiple receptors, meaning inhibitors could suppress inflammatory signals from several sources at once.

There are, of course, caveats. The study measured gene expression in peripheral blood rather than in tumor tissue itself, and while circulating immune cell gene signatures are increasingly used as “liquid biopsy” proxies, the exact cellular source of the elevated transcripts—tumor cells, tumor-associated immune cells, or systemic inflammation—cannot be pinned down from blood alone. The cross-sectional design establishes association, not causation, and the authors note that the work estimates an association between these genes and breast cancer progression rather than proving the pathway drives it. Longitudinal follow-up, correlation with survival outcomes, and tissue-level validation would strengthen the clinical case. Nonetheless, the Egyptian cohort adds an important data point from a population that is underrepresented in cancer genomics research, and the health burden is substantial: breast cancer remains one of the most frequently occurring cancers among women worldwide, and its complex pathophysiology and variety of clinical signs continue to make treatment and prevention challenging.

The research, conducted in accordance with the Declaration of Helsinki and approved by the Ethical Committee of Mansoura University, received no external funding and was carried out with the facilities of the Chemistry Department of the Faculty of Science and the Oncology Center at Mansoura University. As the search for biomarkers that outperform or complement CA 15-3 and CEA continues, the message of this study is that the immune machinery built to sense bacteria may be quietly helping tumors progress—and that listening in on that machinery through a blood sample could offer clinicians a new way to detect, stage, and eventually treat the disease.